SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: Frequency and relation with survival

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4260-4267

  Titulaer, Maarten J ^a   Klooster, Rinse ^a   Potman, Marko ^a   Sabater, Lidia ^a   Graus, Francesc ^a   Hegeman, Ingrid M ^a   Thijssen, Peter E ^a   Wirtz, Paul W ^a   Twijnstra, Albert ^a   Sillevis Smitt, Peter A E ^a   Van Der Maarel, Silve ^a   Verschuuren, Jan J G M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ANTIBODY; PROTEIN HELN1; PROTEIN HUC; PROTEIN HUD; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR SOX1; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX21; TRANSCRIPTION FACTOR SOX3; TUMOR MARKER; UNCLASSIFIED DRUG; AUTOANTIBODY; TRANSCRIPTION FACTOR SOX;

ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER CONTROL; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; EATON LAMBERT SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARANEOPLASTIC SYNDROME; POLYNEUROPATHY; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SURVIVAL; TUMOR IMMUNITY; WESTERN BLOTTING; BLOOD; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; LUNG TUMOR;

AUTOANTIBODIES; BLOTTING, WESTERN; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; LUNG NEOPLASMS; PARANEOPLASTIC SYNDROMES; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CARCINOMA; SOXB1 TRANSCRIPTION FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349315330     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6169     Document Type: Article

References (33)

1. Berrino F, De Angelis R, Sant M, et al: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: Results of the EUROCARE-4 study. Lancet Oncology 8:773-783, 2007
2. Weir HK, Thun MJ, Hankey BF, et al: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95:1276-1299, 2003
3. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006
4. Paesmans M, Sculier JP, Lecomte J, et al: Prognostic factors for patients with small cell lung carcinoma: Analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89:523-533, 2000
5. Gure AO, Stockert E, Scanlan MJ, et al: Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 97:4198-4203, 2000
6. Kiefer JC: Back to basics: Sox genes. Dev Dyn 236:2356-2366, 2007
7. Bylund M, Andersson E, Novitch BG, et al: Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci 6:1162-1168, 2003
8. Sandberg M, Kallstrom M, Muhr J: Sox21 promotes the progression of vertebrate neurogenesis. Nat Neurosci 8:995-1001, 2005
9. Sabater L, Titulaer M, Saiz A, et al: SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 70:924-928, 2008
10. Vural B, Chen LC, Saip P, et al: Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 103:2575-2583, 2005
11. O'Neill JH, Murray NMF, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome: A review of 50 cases. Brain 111:577-596, 1988
12. Sanders DB: Lambert-Eaton myasthenic syndrome: Clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 37: S63-S73, 1995 (suppl 1)
13. Roberts A, Perera S, Lang B, et al: Paraneoplastic myasthenic syndrome IgG inhibits Ca-45(2+) flux in a human small cell-carcinoma line. Nature 317:737-739, 1985
14. Benatar M, Blaes F, Johnston I, et al: Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimmunol 113:153-162, 2001
15. Rudnicki SA, Dalmau J: Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 18:598-603, 2005
16. Graus F, Dalmou J, Rene R, et al: Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival. J Clin Oncol 15:2866-2872, 1997
17. Maddison P, Newsom-Davis J, Mills KR, et al: Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353:117-118, 1999
18. Maddison P, Lang B: Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol 201-202:159-162, 2008
19. Wirtz PW, Lang B, Graus F, et al: P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 164:161-165, 2005
20. Monstad SE, Drivsholm L, Storstein A, et al: Hu and voltage-gated calcium channel (VGCC) anti-bodies related to the prognosis of small-cell lung cancer. J Clin Oncol 22:795-800, 2004
21. Mason WP, Graus F, Lang B, et al: Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120:1279-1300, 1997
22. Lang B, Evoli A: SOX1 autoantibodies: Tumor markers in LEMS patients? Neurology 70:906-907, 2008
23. Wirtz PW, Willcox N, van der Slik AR, et al: HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 159:230-237, 2005
24. Titulaer MJ, Wirtz PW, Willems LN, et al: Screening for small-cell lung cancer: A follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 26:4276-4281, 2008
25. Titulaer MJ, Verschuuren JJ: Lambert-Eaton myasthenic syndrome: Tumor versus nontumor forms. Ann N Y Acad Sci 1132:129-134, 2008
26. Bataller L, Wade DF, Graus F, et al: Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 62:778-782, 2004
27. Monstad SE, Drivsholm L, Skeie GO, et al: CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol Immunother 57:227-232, 2008
28. Sabater L, Bataller L, Suarez-Calvet M, et al: ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol 201-202:163-165, 2008
29. Titulaer MJ, Wirtz PW, Kuks JB, et al: The Lambert-Eaton myasthenic syndrome 1988-2008: A clinical picture in 97 patients. J Neuroimmunol 201-202:153-158, 2008
30. Gill S, Murray N, Dalmau J, et al: Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer. Can J Neurol Sci 30:269-271, 2003
31. Darnell RB, DeAngelis LM: Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 341:21-22, 1993
32. Pujol JL, Godard AL, Jacot W, et al: Spontaneous complete remission of a non-small cell lung cancer associated with anti-Hu antibody syndrome. J Thorac Oncol 2:168-170, 2007
33. Zaheer W, Friedland ML, Cooper EB, et al: Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy. Cancer Invest 11:306-309, 1993